Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of irreversible small molecules to treat patients with genetically defined cancers. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective irreversible inhibitor of MENIN, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was founded in 2017 and is based in Redwood City, California.
$8.95 +0.35 (4.01%)
As of 01/26/2023 16:00:00 EST IEX book CBOE book
2022 © Stock Market MBA, Inc.